Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat
Mereo BioPharma and Sentynl Therapeutics have signed an option and licence agreement related to the US commercial and worldwide manufacturing rights to alvelestat, a potential oral treatment for AATD-LD.
Read the full article on the original site.
Read Full Article